Enlivex (ENLV) Earnings Date & Reports

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis... Show more

Industry: #Medical Specialties

Get AI intraday signals

A.I. Advisor

published Earnings

ENLV is expected to report earnings to rise 293.50% to -7 cents per share on August 24

Q2'26

Est.

$-0.08

Q1'26

Beat

by $0.06

Q4'25

Est.

$-0.14

Q3'25

Beat

by $0.03

Q2'25

Beat

by $0.04

The last earnings report on May 22 showed earnings per share of -1 cents, beating the estimate of -7 cents. With 244.50K shares outstanding, the current market capitalization sits at 204.87M.

View a ticker or compare two or three

Compare

ENLV

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for ENLV